共 50 条
- [31] Efficacy and safety outcomes up to ∼4 years of treatment with filgotinib 200mg among SELECTIONLTE patients with ulcerative colitisGUT, 2023, 72 (SUPPL_2) : A39 - A40Arnott, IanFeagan, BrianMatsuoka, KatsuyoshiRogler, GerhardFaes, MargauxOortwijn, Alessandrade Haas, AngelaRudolph, ChristinePeyrin-Biroulet, Laurent
- [32] Effect of Baseline MTX Dose on Clinical Efficacy and Safety in Rheumatoid Arthritis Patients Treated with Filgotinib: Post-Hoc Analysis from a Phase 2B StudyARTHRITIS & RHEUMATOLOGY, 2017, 69Westhovens, Renevan der Aa, AnnegretJamoul, CorinneTasset, ChantalHarrison, Pille
- [33] Factors associated with partial Mayo Clinic Score over time in patients with Ulcerative Colitis treated with filgotinib in the phase 2b/3 SELECTION trialJOURNAL OF CROHNS & COLITIS, 2023, 17 : 866 - 866Peyrin-Biroulet, L.Louis, E.Hisamatsu, T.Jamoul, C.Santermans, E.Harris, K.de Haas, A.Oortwijn, A.Feagan, B.
- [34] EARLY ACHIEVEMENT OF PARTIAL MAYO SCORE REMISSION AND IBDQ NORMALIZATION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDYGASTROENTEROLOGY, 2021, 160 (06) : S352 - S353Vermeire, SeverineOortwijn, AlessandraFeagan, Brian G.Yun, ChoheeZhang, JiePeyrin-Biroulet, LaurentFerrante, MarcDanese, Silvio
- [35] Evaluation of Ozanimod Efficacy and Safety in Older Patients With Ulcerative Colitis: Post Hoc Analysis From the Phase 3 True North StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S580 - S581Khan, NabeelIrving, PeterBlumenstein, IrinaHorst, Sara N.Ahmad, Harris A.Lawlor, GarrettHobbs, VanessaJain, AnjaliMemaj, ArteidAnanthakrishnan, Ashwin N.
- [36] Efficacy and safety outcomes up to ∼4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE studyJOURNAL OF CROHNS & COLITIS, 2023, 17 : I47 - I49Feagan, B. G.Matsuoka, K.Rogler, G.Faes, M.Oortwijn, A.de Haas, A.Rudolph, C.Peyrin-Biroulet, L.
- [37] Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION StudyJOURNAL OF CROHNS & COLITIS, 2023, 17 (02): : 211 - 220Loftus, Edward V., Jr.Vermeire, SeverineFeagan, Brian G.Le Brun, Franck-OlivierOortwijn, AlessandraMoerch, UlrikSandborn, William J.Hibi, Toshifumi
- [38] EFFECT OF BASELINE SERUM CRP LEVELS ON CLINICAL EFFICACY IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH FILGOTINIB: POST-HOC ANALYSIS FROM TWO PHASE 2B STUDIESANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 148 - 148Westhovens, R.Kavanaugh, A.Jamoul, C.Tasset, C.Harrison, P.Van der Aa, A.
- [39] No Effect of Baseline Serum CRP Levels on Clinical Efficacy Parameters in Rheumatoid Arthritis Patients Treated with Filgotinib: Post Hoc Analysis from Two Phase 2B StudiesARTHRITIS & RHEUMATOLOGY, 2017, 69Kavanaugh, ArthurVan der Aa, AnnegretJamoul, CorinneTasset, ChantalHarrison, PilleWesthovens, Rene
- [40] EFFICACY AND SAFETY OF PRUCALOPRIDE IN PATIENTS WITH CHRONIC IDIOPATHIC CONSTIPATION STRATIFIED BY AGE: A POST HOC ANALYSIS OF PHASE 3 AND 4 CLINICAL TRIALSGASTROENTEROLOGY, 2022, 162 (07) : S925 - S925Lembo, AnthonyBoules, MenaFeuerstadt, PaulKunkel, David C.Staller, KyleSpalding, WilliamGabriel, AndreYoussef, AshrafXie, YunlongWan, YapingTerreri, BrianCash, Brooks D.